Equities

Celcuity Inc

CELC:NAQ

Celcuity Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)21.60
  • Today's Change3.44 / 18.94%
  • Shares traded606.29k
  • 1 Year change+108.09%
  • Beta0.7572
Data delayed at least 15 minutes, as of Mar 28 2024 20:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Celcuity, Inc. is a clinical-stage biotechnology company focused on the development of targeted therapies for treatment of multiple solid tumor indications. Its CELsignia companion diagnostic platform is able to analyze live patient tumor cells to identify new groups of cancer patients to benefit from targeted therapies. Its lead therapeutic candidate is gedatolisib, a potent, small molecule dual inhibitor that selectively targets all Class I isoforms of PI3K and mammalian target of rapamycin (mTOR). Its mechanism of action and pharmacokinetic properties are highly differentiated from other investigational therapies that target PI3K or mTOR alone or together. Its initial clinical development program for gedatolisib focus on the treatment of patients with hormone receptor positive (HR+), HER2-negative, advanced or metastatic breast cancer. Its VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer.

  • Revenue in USD (TTM)0.00
  • Net income in USD-56.51m
  • Incorporated2017
  • Employees45.00
  • Location
    Celcuity Inc16305 36th Ave N Ste 100MINNEAPOLIS 55446-4285United StatesUSA
  • Phone+1 (763) 392-0767
  • Fax+1 (302) 655-5049
  • Websitehttps://www.celcuity.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
AVITA Medical Inc50.14m-35.38m424.16m207.00--8.64--8.46-1.40-1.401.981.910.47781.968.48242,236.70-33.71---38.04--84.93---70.56--7.46-35.400.448--45.68---32.69------
Shattuck Labs Inc1.66m-87.30m426.32m75.00--2.93--257.29-2.05-2.050.03893.060.0091----22,093.33-47.85-29.14-53.15-32.42-----5,268.44-565.33----0.00--154.14-40.6214.37---19.15--
Theravance Biopharma Inc57.42m-55.19m433.96m99.00--2.03--7.56-0.9704-0.97041.044.430.1161--3.35580,040.40-11.16-40.51-11.79-48.50-----96.11-305.27----0.00--11.84-0.995640.54---19.24--
Jasper Therapeutics Inc0.00-64.47m434.14m45.00--4.10-----6.19-6.190.007.030.00----0.00-90.00---104.13--------------0.00-------71.06------
Celcuity Inc0.00-56.51m439.53m45.00--4.37-----2.73-2.730.004.150.00----0.00-54.42-37.87-60.02-39.28------------0.2821-------36.36---7.92--
Invivyd Inc0.00-169.56m440.46m84.00--1.78-----1.55-1.550.002.240.00----0.00-48.47---54.11--------------0.00-------6.41------
Avid Bioservices Inc140.94m-11.45m441.41m365.00--2.40--3.13-0.1816-0.18162.232.900.31443.185.49386,131.50-2.5510.73-3.1114.0112.5222.72-8.1225.920.8529-3.320.45020.0024.8122.72-99.56--82.90--
Harrow Inc130.19m-24.41m450.17m315.00--6.33--3.46-0.7448-0.74483.992.010.55464.556.13413,311.10-10.40-10.86-12.14-12.7169.5570.75-18.75-15.352.610.04450.7223--46.9525.77-73.30--143.88--
Alto Neuroscience Inc0.00-32.74m451.11m63.00---------1.28-1.280.001.41------0.00--------------------0.2133---100.00---201.62------
Aeon Biopharma Inc0.00-28.71m452.60m10.00----103.55---0.7727-0.77270.00-3.28------0.00------------------0.5686--------5.54------
OraSure Technologies, Inc.405.47m53.66m453.11m638.008.521.056.071.120.72040.72045.475.860.87483.157.31635,536.1011.580.723813.110.821244.2546.9413.231.138.57--0.00180.004.6417.41413.1782.2010.18--
PepGen Inc0.00-78.63m455.87m64.00--3.10-----3.30-3.300.004.550.00----0.00-43.62---48.51--------------0.00-------13.78------
Inozyme Pharma Inc0.00-71.17m456.49m59.00--3.25-----1.39-1.390.002.270.00----0.00-41.86-45.00-45.82-48.90------------0.2417-------6.13--2.85--
Ocugen Inc0.00-75.53m456.57m84.00--7.82-----0.3242-0.32420.000.22770.00----0.00-79.11-83.81-91.61-96.15-------446,793.90----0.0453-------39.38--74.43--
Data as of Mar 28 2024. Currency figures normalised to Celcuity Inc's reporting currency: US Dollar USD

Institutional shareholders

45.44%Per cent of shares held by top holders
HolderShares% Held
Soleus Capital Management LP (Investment Management)as of 31 Dec 20232.18m9.01%
Morgan Stanley & Co. LLCas of 31 Dec 20232.12m8.75%
Commodore Capital LPas of 31 Dec 20231.75m7.25%
Perceptive Advisors LLCas of 31 Dec 20231.48m6.12%
BlackRock Fund Advisorsas of 31 Dec 2023954.15k3.94%
The Vanguard Group, Inc.as of 31 Dec 2023809.10k3.34%
CapFinancial Partners LLCas of 31 Dec 2023544.84k2.25%
Baker Bros. Advisors LPas of 31 Dec 2023535.48k2.21%
Geode Capital Management LLCas of 31 Dec 2023323.43k1.34%
SSgA Funds Management, Inc.as of 31 Dec 2023296.66k1.23%
More ▼
Data from 31 Dec 2023 - 31 Dec 2023Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.